Combatting the Monkeypox epidemic with Fapon Biotech's advanced diagnostic solutions. Our high-sensitivity, high-specificity antigen tests provide rapid and reliable results.
 |
| Fapon Biotech leads the charge against monkeypox with its cutting-edge antigen diagnostic. Our test delivers accurate results quickly, supporting global health efforts. |
Shenzhen, China, Aug. 18, 2024:
As the global health community grapples with the ongoing monkeypox outbreak, Fapon Biotech, a pioneer in In-vitro Diagnostics (IVD) solutions, is at the forefront of developing innovative diagnostic tools to combat this emerging threat. The company's steadfast commitment to advancing global health is underscored by its rapid response to the World Health Organization's (WHO) declaration of monkeypox as a Public Health Emergency of International Concern (PHEIC) on August 14.
Fapon Biotech has been at the forefront of addressing the diagnostic challenges posed by monkeypox since the initial outbreak in 2022. Through continuous research and development, the company has refined its raw materials for monkeypox antigen rapid tests, resulting in products that exhibit exceptional sensitivity and specificity. Notably, Fapon's tests have demonstrated no cross-reactivity with related viruses, ensuring accurate and reliable results.
A critical aspect of Fapon Biotech's mission is to make diagnostic solutions accessible to all, particularly in low- and middle-income countries. The company's commitment to developing user-friendly and affordable tests is aligned with the global effort to contain the spread of monkeypox. The increasing global circulation of the monkeypox virus in 2023 highlighted the urgent need for decentralized diagnostic solutions that can be deployed effectively in diverse healthcare settings.
In response to this critical need, the WHO has established a target product profile for monkeypox diagnostics to facilitate the development of point-of-care (POC) tests. These tests are designed to be easily administered in community settings, making them invaluable tools for early detection and outbreak control. Fapon Biotech is actively contributing to this initiative by developing POC tests that meet the WHO's stringent requirements.
With a rich history spanning over two decades, Fapon Biotech has a proven track record in developing IVD solutions for a wide range of infectious diseases, including HIV, hepatitis C, syphilis, malaria, dengue, and respiratory illnesses. This deep-rooted expertise positions the company as a trusted partner in the fight against emerging pathogens.
Looking ahead, Fapon Biotech is leveraging its advanced antibody design capabilities and cutting-edge technology to develop diagnostic tests that offer even earlier detection and improved clinical outcomes. By providing high-performance IVD reagent raw materials, reagent services, and innovative open instrument platforms, the company is empowering its global partners to create a new generation of diagnostic solutions.
Fapon Biotech's vision is to enable a world where everyone has access to timely and accurate diagnostics. By collaborating with the global health community, the company is committed to delivering on this promise and making a significant impact on public health.
Fapon Biotech is a global leader in the In-vitro Diagnostics (IVD) industry, dedicated to advancing global health through innovative diagnostic solutions. With a focus on delivering earlier, more accurate, convenient, and accessible diagnostics, Fapon Biotech is committed to enabling the development of the diagnostics industry with its global partners.